Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

利比韦林 耐受性 医学 临床终点 养生 不利影响 内科学 人口 病毒载量 临床研究阶段 随机对照试验 临床试验 外科 人类免疫缺陷病毒(HIV) 抗逆转录病毒疗法 病毒学 环境卫生
作者
Giuliano Rizzardini,Edgar Turner Overton,Chloe Orkin,Susan Swindells,Keikawus Arastéh,Miguel Górgolas Hernández-Mora,Vadim Pokrovsky,Pierre Marie Girard,Shinichi Oka,Jaime Andrade-Villanueva,Gary Richmond,Axel Baumgarten,Mar Masiá,Gulam H Latiff,Sandy Griffith,Conn M Harrington,Krischan J Hudson,Marty St. Clair,Christine L. Talarico,Parul Patel,Amy Cutrell,Veerle Van Eygen,Ronald D’Amico,Joseph Mrus,Sterling Wu,Susan L. Ford,K.-C. Chow,Jeremy Roberts,Angela Wills,Nicola Walters,Simon Vanveggel,Rodica Van Solingen‐Ristea,Herta Crauwels,Kimberly Y. Smith,William Spreen,David Margolis
出处
期刊:Journal of Acquired Immune Deficiency Syndromes [Lippincott Williams & Wilkins]
卷期号:85 (4): 498-506 被引量:78
标识
DOI:10.1097/qai.0000000000002466
摘要

Background: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies. Methods: Adult participants with virologic suppression (plasma HIV-1 RNA <50 copies/mL) were randomized (1:1) to continue with their current antiretroviral regimen (CAR) or switch to the long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In the LA arm, participants initially received oral CAB + RPV once-daily for 4 weeks to assess individual safety and tolerability, before starting monthly injectable therapy. The primary endpoint of this combined analysis was antiviral efficacy at week 48 (FDA Snapshot algorithm: noninferiority margin of 4% for HIV-1 RNA ≥50 copies/mL). Safety, tolerability, and confirmed virologic failure (2 consecutive plasma HIV-1 RNA ≥200 copies/mL) were secondary endpoints. Results: The pooled intention-to-treat exposed population included 591 participants in each arm [28% women (sex at birth), 19% aged ≥50 years]. Noninferiority criteria at week 48 were met for the primary (HIV-1 RNA ≥50 copies/mL) and key secondary (HIV-1 RNA <50 copies/mL) efficacy endpoints. Seven individuals in each arm (1.2%) developed confirmed virologic failure; 6/7 (LA) and 3/7 (CAR) had resistance-associated mutations. Most LA recipients (83%) experienced injection site reactions, which decreased in incidence over time. Injection site reactions led to the withdrawal of 6 (1%) participants. The serious adverse event rate was 4% in each arm. Conclusion: This combined analysis demonstrates monthly injections of CAB + RPV LA were noninferior to daily oral CAR for maintaining HIV-1 suppression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Julian的应助被小叶不吃香菜采纳,获得30
刚刚
聪明荆关注了科研通微信公众号
1秒前
深情安青的应助被richardhipower采纳,获得10
1秒前
研友_Z30GJ8发布了新的文献求助10
2秒前
Alive发布了新的文献求助10
3秒前
zzz完成签到,获得积分10
3秒前
4秒前
沉默海莲完成签到 ,获得积分10
5秒前
5秒前
李健成完成签到,获得积分10
5秒前
onmyway完成签到,获得积分10
5秒前
天真豪英完成签到 ,获得积分10
6秒前
zhhh完成签到,获得积分10
6秒前
7秒前
7秒前
zzh_zxc完成签到,获得积分10
9秒前
10秒前
李爱国的应助被richardhipower采纳,获得10
12秒前
13秒前
Hello的应助被TT采纳,获得10
15秒前
望禾完成签到,获得积分10
15秒前
XX完成签到,获得积分10
18秒前
19秒前
handsomeboy完成签到,获得积分10
20秒前
22秒前
137292967发布了新的文献求助10
23秒前
张磊发布了新的文献求助10
23秒前
23秒前
FashionBoy的应助被richardhipower采纳,获得10
23秒前
田様的应助被Cylara采纳,获得10
25秒前
可爱的函函的应助被yuyuyu采纳,获得10
25秒前
26秒前
无助的考拉完成签到,获得积分10
26秒前
26秒前
26秒前
张张发布了新的文献求助10
27秒前
28秒前
K9999K发布了新的文献求助10
28秒前
Lydia发布了新的文献求助10
28秒前
在水一方的应助被zww采纳,获得10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192604
求助须知:如何正确求助?哪些是违规求助? 9579105
关于积分的说明 21863529
捐赠科研通 7792211
什么是DOI,文献DOI怎么找? 3436974
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864